Hepatic encephalopathy, viral hepatitis scoring, and cirrhosis mortality prediction.
Predicts survival in patients with alcoholic hepatitis at 90 days and 1 year, based on age, bilirubin, creatinine, and INR
Predicts survival in hepatocellular carcinoma patients based on serum albumin and bilirubin concentrations
Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C using readily available laboratory values.
Predicts risk of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The BARD score uses three simple clinical parameters (BMI, AST/ALT ratio, and diabetes) to identify patients at low risk of advanced fibrosis who may not require liver biopsy.
The PALBI grade stratifies liver reserve in cirrhosis/HCC from bilirubin, albumin and platelets. Accepts common clinical units and normalizes internally (bilirubin to umol/L, albumin to g/L).
Classifies drug-induced liver injury pattern: >=5 hepatocellular, 2-5 mixed, <=2 cholestatic.
Clinical Decision Support (CDS) Notice & Legal Disclaimer
All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.